Stefan Troller

This presentation will introduce age-related Macular Degeneration (AMD) affects about one-quarter of individuals over 60, leading to central vision loss and a reduced quality of life. While treatments are available and new therapies are continually being developed, accurate disease state monitoring remains crucial for both successful drug development and effective administration. The ecosystem of drug delivery devices for AMD treatments involves a network of stakeholders, including pharmaceutical companies developing anti-VEGF drugs, healthcare providers diagnosing and administering treatments, and advanced diagnostic devices monitoring disease progression. This presentation will introduce this ecosystem focusing on the administration and diagnostic aspects by highlighting examples of innovative tools for assessing AMD, incl. home use devices, that improve overall disease management and characterization of clinical end points.